News

Andrew Lees, MD FRCP, FMedSci, Professor of Neurology, (The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila, Weston Institute of Neurological Studies, University

The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for cabozantinib compared with sunitinib in patients with advanced intermediate-

Vtesse’s ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial is a three-part, efficacy and safety trial of VTS-270, administered by the lumbar intrathecal (IT) route every two weeks.

Rituximab is a monoclonal antibody that is used to treat non-Hodgkin’s lymphoma, which includes follicular lymphoma and diffuse large B-cell lymphoma, chronic lymphocytic leukemia and autoimmune diseases such

A new research team of scientists established by the companies had submitted the most promising solution approaches in a crowdsourcing competition. The interdisciplinary team, which will be led

Darzalex, which is being developed jointly by Genmab and Janssen Biotech, is a human IgG1k monoclonal antibody that binds to CD38, a protein expressed on the surface of

The objective of SPARTAN is to evaluate the safety and efficacy of lasmiditan (50 mg, 100 mg and 200 mg) in comparison to placebo two hours after dosing

Patients will be at least 18 years of age with a maximum of 10% treatable body surface area (BSA) involvement of plaque psoriasis. Up to 15 patients will

Anavex Life Sciences president and CEO Christopher U. Missling said: "The Orphan Drug Designation marks the first U.S. movement for ANAVEX 2-73. Rett syndrome is a devastating disease